1. Home
  2. News
  3. Delta-Fly Pharma, Inc.
  4. Announcement Regarding the Acceptance of Two DFP-10917 Clinical Study Presentations at ASH 2026
More Delta-Fly Pharma, Inc. news
Delta-Fly Pharma, Inc.TSE: 4598

Announcement Regarding the Acceptance of Two DFP-10917 Clinical Study Presentations at ASH 2026

Nov 5, 2026 at 1:30 AM EST · Issued by Delta-Fly Pharma, Inc. via TDnet

Filed with TSE · Nov 5, 2026 at 1:30 AM EST · 1 page · English

On 6ix: 6ix.com/news/announcement-regarding-the-acceptance-of-two-dfp-10917-clinical-study-presentations-at-ash-2026

Delta-Fly Pharma, Inc. on 6ix

Earlier from Delta-Fly Pharma

  • Update on the Phase 2/3 Clinical Trial of DFP-17729Aug 31
  • Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with VenetoclaxMar 3, 2025
  • Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with VenetoclaxDec 9, 2024
  • Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729Dec 4, 2024
  • Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323Nov 26, 2024

Later from Delta-Fly Pharma

  • Announcement Regarding Patent Allowance for a Long-Term Stable Formulation of DFP-10917Nov 18
All Delta-Fly Pharma news releases↗

Follow Delta-Fly Pharma into a list and get an email when it puts out news.

Follow Delta-Fly Pharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer